A New Drug Shows Promise for the Hallucinations and Delusions That Plague 75% of Lewy Body Dementia Patients

A new experimental drug called zervimesine has shown significant promise in treating the psychiatric symptoms that affect as many as 75% of patients with dementia with Lewy bodies (DLB), a condition where hallucinations, delusions, and aggression often lead to institutionalization. Unlike traditional antipsychotics that can worsen movement problems in DLB patients, zervimesine improved neuropsychiatric symptoms while preserving motor function, according to Phase 2 trial results.

What Is Dementia with Lewy Bodies and Why Is Psychosis Such a Problem?

Dementia with Lewy bodies is a progressive brain disorder caused by the buildup of abnormal proteins called alpha-synuclein in nerve cells. This protein accumulation damages neurons and leads to cognitive decline, movement problems, and behavioral changes. The psychiatric symptoms—hallucinations, delusions, anxiety, aggression, and agitation—are particularly devastating because they're not just distressing for patients; they also accelerate the need for institutional care and increase healthcare costs.

The challenge has been that standard antipsychotic medications, such as haloperidol, are actually contraindicated in DLB patients. These drugs can trigger severe parkinsonism, sedation, and immobility in people with Lewy bodies, making their condition worse rather than better. This has left DLB patients with few treatment options for their psychiatric symptoms, creating what experts describe as a critical unmet medical need.

How Did Zervimesine Perform in Clinical Trials?

Cognition Therapeutics conducted the SHIMMER study, which enrolled 130 adults with mild-to-moderate DLB and randomized them to receive either zervimesine (at 100 or 300 milligrams daily) or placebo for six months. The results were encouraging across multiple symptom domains. Most notably, zervimesine slowed the decline of neuropsychiatric symptoms by 86% compared to placebo, as measured by the 12-item Neuropsychiatric Inventory (NPI-12), a validated tool that assesses hallucinations, delusions, and behavioral disturbances.

What makes these findings particularly significant is that zervimesine achieved these psychiatric benefits without impairing motor skills. In fact, the drug showed directionally favorable effects on cognitive fluctuations, memory, movement, and activities of daily living—areas where traditional antipsychotics typically cause harm. "There are no approved medications for DLB psychosis, which affects a majority of patients with the disease," explained Lisa Ricciardi, president and CEO of Cognition Therapeutics. "Traditional antipsychotics and benzodiazepines can worsen motor function in DLB patients. We showed in Phase 2 that zervimesine's impact on neuropsychiatric symptoms did not impair participants' motor skills."

How Does Zervimesine Work in the Brain?

Zervimesine is an oral medication that works through a mechanism distinct from other dementia treatments. The drug targets the sigma-2 receptor, a protein in the brain that plays a role in neurodegeneration. By interacting with this receptor, zervimesine interrupts the toxic effects of both amyloid-beta (a protein implicated in Alzheimer's disease) and alpha-synuclein (the protein that accumulates in Lewy body dementia). This dual action allows the drug to address the underlying protein damage that drives cognitive and psychiatric decline in DLB patients.

What's Next for Zervimesine Development?

Based on the FDA's feedback from a Type C meeting held in January 2026, Cognition Therapeutics has decided to pursue a registrational pathway specifically for DLB psychosis. The company plans to design a new clinical trial that will focus on measuring neuropsychiatric symptoms such as hallucinations and delusions, as well as behavioral symptoms including anxiety, aggression, and agitation. Participants will be randomized to either 100 milligrams of oral zervimesine or placebo daily, with the option to enroll in an open-label extension study afterward.

Cognition expects to meet with the FDA's Division of Psychiatry by mid-year 2026 to discuss the DLB psychosis program further. This regulatory strategy could accelerate zervimesine's path to market, potentially bringing the first FDA-approved treatment for DLB psychosis to patients within the next few years.

Steps to Understanding Your DLB Treatment Options

• Recognize Psychiatric Symptoms Early: If you or a loved one with DLB experiences hallucinations, delusions, aggression, or severe anxiety, discuss these symptoms with a neurologist or geriatrician rather than assuming they're untreatable or accepting standard antipsychotics without exploring alternatives.
• Avoid Contraindicated Medications: Ensure your healthcare provider knows you have DLB before prescribing any antipsychotic medication, as drugs like haloperidol can worsen movement and motor function in ways that accelerate decline.
• Ask About Clinical Trials: If you're interested in accessing zervimesine or other experimental treatments, ask your neurologist about ongoing clinical trials in your area or contact the Lewy Body Dementia Association for resources and trial information.
• Monitor Multiple Symptom Domains: Work with your care team to track not just psychiatric symptoms but also cognitive function, memory, movement, and ability to perform daily activities, since some treatments may help one area while harming another.

Why This Matters for Patients and Families

The psychiatric symptoms of DLB are often the reason families decide to move a loved one to institutional care. Hallucinations and delusions can be terrifying for patients, and aggression or agitation can strain caregivers to the breaking point. The fact that zervimesine addresses these symptoms without worsening movement problems represents a genuine breakthrough for a population that has had almost no good options. The SHIMMER study was supported by a $30 million grant from the National Institute on Aging at the National Institutes of Health and was conducted in collaboration with leading DLB researchers at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association, lending credibility to the findings.

While zervimesine is not yet approved by the FDA, the regulatory pathway forward suggests that patients may have access to this treatment within a reasonable timeframe. For families currently struggling with the behavioral and psychiatric manifestations of DLB, this news offers hope that relief may be on the horizon.